The deal advances Galapagos' plan to develop a decentralized CAR T-cell therapy for non-Hodgkin lymphoma with a one-week vein-to-vein time.

After revenue boomed for biopharma manufacturers during the COVID pandemic, sales have stagnated for several CDMO giants, ...

New option listings for January 22nd include Lennar . Option delistings effective January 22nd include POSEIDA THERAPEUTICS INC. (PSTX), DUCKHORN PORTFOLIO INC. (NAPA), Manitex In ...

Catalent has entered a strategic partnership with Galapagos to facilitate decentralised manufacturing in the US for the ...

Specifically, Catalent's commercial cell therapy manufacturing facility in Princeton, New Jersey, will support manufacturing ...

Catalent, Inc., a leader in enabling the development and supply of better treatments for patients worldwide, today announced a strategic collaboration with Galapagos NV (Euronext & NASDAQ: GLPG), a ...

Will further expand Galapagos’ manufacturing network in the U.S. for improved patient experience.

For the fourth quarter, the Aristotle Small/Mid Cap Equity Composite generated a total return of -0.45% net of fees, ...

Investment analysts at StockNews.com began coverage on shares of Catalent (NYSE:CTLT – Get Free Report) in a report released on Monday. The firm set a “hold” rating on the stock. Other equities ...

The global biologics contract development and manufacturing organization (cdmo) market size is estimated to grow by USD 16.32 ...

TD Cowen analyst Michael Nedelcovych has maintained their bullish stance on NVO stock, giving a Buy rating on January 13.Stay Ahead of the ...

Novo Holdings plans to double its newly acquired contract drugmaker, Catalent, within five years, focusing on U.S. manufacturing. The $16.5 billion acquisition is aimed at enhancing supply chains amid ...